38th WCIM 2026 Taipei, Taiwan

THE 38th WORLD CONGRESS OF INTERNAL MEDICINE 2026

November 12th - 15th

AI, Medicine, Humanity into the Future

Program Book



WCIM 2026 Program Book

Belite BIO



To preserve vision and pioneer degenerative retinal disease treatments where few or none exist today.

Belite Bio® is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical need.

LEARN MORE


Scan to visit belitebio.com

© 2026 Belite Bio. All rights reserved. MAT-0052-1

Intended for Healthcare Professionals Only. NX-TW-HZU-LBND-260001 | Date of preparation: 2026.09 ©2026 GSK group of companies or its licensor
不良事件通報程序：(02)23126836, https://gsk.public.reportum.com 荷商葛蘭素史克藥廠(股)台灣分公司 地址：台北市大同區承德路一段 2 號 20 樓

GSK

Prevent the Preventable



Varicella zoster virus (VZV)

©2026 PRODUCED BY VACCINE MEDICAL AFFAIRS

This image has been independently created by GSK Vaccine Medical Affairs from the original source. It was first published in Zerboni L, Sen N, Oliver SL, Arvin AM. Nat Rev Microbiol. 2014;12(3):197-210. Figure is for illustrative purposes.

TABLE OF CONTENT

1 INTRODUCTION

2 Welcome Message

3 WCIM 2026 Organizing Committee

5 Acknowledgements

7 CONGRESS INFORMATION

8 Congress Overview

10 Congress Services

12 Oral Presentation

13 E-poster Presentation

13 Online Abstracts

17 SCIENTIFIC PROGRAMS

18 Program at a Glance

23 Detailed Program

36 Sponsored Symposium Agenda

43 FLOOR PLAN

46 Exhibition Directory

47 Accreditation Application
(Domestic Delegate Only)

INTRODUCTION



Welcome Message

Dear Members, Colleagues, and Friends,

It is with great honor and heartfelt enthusiasm to welcome all of you to the 38th World Congress of Internal Medicine (WCIM 2026), November 12 to 15, 2026, at the Taipei Nangang Exhibition Center, Hall 2 (TaiNEX 2), in Taipei, Taiwan.

On behalf of the Taiwan Society of Internal Medicine, we are proud to host this prestigious event under the theme "**AI, Medicine, and Humanity into the Future.**" This theme highlights our dedication to advancing internal medicine through innovation, while staying rooted in the humanistic values that define our profession.

WCIM 2026 promises a vibrant and comprehensive program, covering cutting-edge research, medical education, clinical practice, and key subspecialties such as geriatrics, ethics, and critical care. It will be a global platform where experts, clinicians, and researchers come together to exchange ideas, inspire one another, and shape the future of healthcare.

We warmly welcome you to Taipei—a city where ancient traditions blend seamlessly with modern technology. From its rich cultural heritage and world-famous cuisine to its leadership in medicine and science, Taipei offers a truly unique experience.

During WCIM 2026, we hope to celebrate the spirit, dedication, and global impact of internal medicine. Let us learn from one another, build meaningful connections, and strengthen collaboration toward a healthier future for all. We look forward to a successful and memorable meeting in Taipei!



Shan-Chwen Chang

Shan-Chwen Chang
President, WCIM 2026

WCIM 2026

President
Shan-Chwen Chang

Secretary-General
Wang-Huei Sheng

Vice Secretary-General
Ding-Cheng Chan Kuan-Yu Chen

Executive Secretary
Jyh-Ming Liou Chih-Yuan Wang Jenq-Wen Huang

Treasurer
Tien-Shang Huang

Local Organizing Committee

Chairperson
Shan-Chwen Chang

Committee Members
Ming-Fong Chen Pei-Ming Yang Fa-Yauh Lee Hui-Hsiung Liu Chih-Hsin Yang
Shih-Hua Lin

International Society of Internal Medicine (ISIM) Executive Committee

President
Virginia Hood

Past President
John Kolbe

President Elect
Richard Ceska

Secretary-General
Hans-Peter Kohler

Treasurer
Andres Huber

Members
Quazi Tarikul Islam
Sally Aman Nasution
Shan-Chwen Chang
Lorenzo Diaz Salazar
Isaac Opole
Freek Bester

Scientific Program Committee

Chair
Jia-Horng Kao

Deputy Chair
Chong-Jen Yu

Members

Cardiology
Yi-Heng Li, Tzung-Dau Wang, I-Chang Hsieh

Gastroenterology
Jyh-Ming Liou, Tung-Hung Su, Jiing-Chyuan Luo, Han-Mo Chiou

Pulmonology & Critical care
Herbert Joue, Der-Chuen Shiah, Chun-Liang Lai

Nephrology
Huang-Yu Yang, I-Wen Wu, Yu-Tzu Chang

Hematology
Bor-Sheng Ko, Hui-Hua Hsiao, Yuan-Bin Yu

Immunology
Yen-Po Tsao, Wen-Yi Tseng

Endocrinology
Ming-Nan Chien, Horng-Yih Ou

Metabolism (Diabetes)
Yi-Sun Yang, Tien-Jyun Chang

Rheumatology
Ming-Han Chen, Shih-Chang Lin, Guang-Huei Yu

Infection Diseases
Jann-Tay Wang, Ching-Tai Huang, Yu-Jiun Chan

Oncology
Ming-Huang Chen, Wei-Wu Chen, De-Rek Huang

Acknowledgements

The Organizing Committee of the 38th World Congress of Internal Medicine (WCIM 2026) would like to extend its sincere gratitude to the following organizations and sponsors. Without their generous support, the Congress would not be such a great success.

Supporting Organizations

NSTC 國家科學及技術委員會 National Science and Technology Council

TAIPEI 觀光傳播局 Department of Information and Tourism

中華民國外交部 Ministry of Foreign Affairs Republic of China (Taiwan)

Sponsors

Diamond Sponsors

Belite BIO

GSK

台灣精品 TAIWAN EXCELLENCE

台灣區電機電子工業同業公會 Taiwan Electrical and Electronic Manufacturers' Association

Platinum Sponsors

Boehringer Ingelheim 百靈佳殷格翰

moderna 莫德納台灣

Gold Sponsors

Lin BioScience

novo nordisk®

Exhibitors

AMBOSS

ACP American College of Physicians

Broad

華鋒科技 Eastech

Lilly

ELSEVIER

ERA bioteq 艾柏生技

GenMont Biotech Incorporation

Jello

LeSONO

JET 立捷醫療儀器有限公司

LISTEN

Pfizer

PIEBM

Quanta Computer

衛生福利部 食品藥物管理署 FDA Taiwan Food and Drug Administration

台灣塩野義藥

UDB

Veeva

沃醫學集團 WOH MEDICAL

Supporters

abbvie

GILEAD

MSD

友華集團 OEP GROUP

Jardiance® 恩排糖®
(empagliflozin)



Jardiance® 提供「糖、心、腎」全方位保護力

T2D

用於成人及 10 歲以上小兒之 T2D 病人的**血糖控制**

用於 T2D 且已有心血管疾病的成人病人時，可**降低心血管原因死亡的風險**

HF

用於 NYHA 第二級至第四級的心臟衰竭成年病人，**可降低心血管死亡**和**心臟衰竭住院風險**，並**減緩 eGFR 的下降**

CKD

降低腎臟疾病惡化(eGFR 持續降低、末期腎臟疾病或腎臟死亡) 或**心血管死亡風險**

降低全因性住院風險

不論 T2D、HF、CKD 病人

Jardiance® 10 mg
一天一錠，不論腎功能皆能持續使用



由於經驗有限，針對透析病人，不建議使用 Jardiance® 作為起始治療。

Abbreviation: CKD = chronic kidney disease; eGFR = estimated glomerular filtration rate; HF = heart failure; T2D = type 2 diabetes mellitus.
References: Jardiance® 10 mg 仿單。

恩排糖® 膜衣錠 10 毫克 Jardiance® 10 mg Film Coated Tablets　衛部藥輸字第 026406 號

1. 適應症與用法：1.1 第二型糖尿病 1.1.1 血糖控制：用於成人及 10 歲以上小兒之第二型糖尿病病人 1.1.2 預防心血管事件：用於具第二型糖尿病且已有心血管疾病的成人病人時，可降低心血管原因死亡的風險。1.2 心臟衰竭 JARDIANCE 10 mg 用於紐約心臟學會 (NYHA) 第二級至第四級的心臟衰竭成年病人，可：．降低心血管死亡和心臟衰竭住院風險。．減緩預估腎絲球過濾率 (eGFR) 下降。1.3 慢性腎臟病：適用於患有慢性腎臟病的成人病人，以降低以下風險：．腎臟疾病惡化（預估腎絲球過濾率 (eGFR) 持續降低、末期腎臟疾病或腎臟死亡）或心血管死亡，全因性住院。1.4 使用上的限制 JARDIANCE 不建議用於第一型糖尿病病人，其可能會增加遮蔽病人酮酸中毒的風險。對於 eGFR 低於 30 mL/min/1.73m² 的第二型糖尿病成人病人，不建議使用 JARDIANCE 改善其血糖控制。根據其作用機制，JARDIANCE 在此情況下可能無療效。2 用法用量：本藥須由醫師處方使用 2.1 開始使用 JARDIANCE 之前：請在開始使用 JARDIANCE 治療前及治療中認為有必要時，進行腎功能評估。針對體液容量減少的病人，開始服用 JARDIANCE 前先矯治此一狀況。2.2 第二型糖尿病：JARDIANCE 可單獨使用亦可與 metformin、metformin 併用 sulfonylurea、pioglitazone (併用或不併用 metformin)、胰島素 (併用或不併用 metformin 及 / 或 sulfonylurea) 合併使用，作為附加於飲食控制及運動之外的治療藥物，藉以改善第二型糖尿病病人的血糖控制效果。JARDIANCE 的建議劑量為每天早上一次，每次 10 mg，可與食物一起服用，亦可空腹服用。當耐受性良好且病人 eGFR ≥30 mL/min/1.73m²，需要進一步的血糖控制時，可將劑量提升至 25 mg。2.3 心臟衰竭：JARDIANCE 的建議劑量為每天早上一次、每次 10 mg，可與食物一起服用。亦可空腹服用。2.4 慢性腎臟病：JARDIANCE 的建議劑量為每天一次、每次 10 mg。2.5 關於漏服劑量的建議：如果漏服劑量，請指示病人盡快服用該劑量。告知病人勿加倍服用下個劑量。2.6 小兒族群：第二型糖尿病：JARDIANCE 的建議劑量為每天 10 mg。當耐受性良好，需要進一步的血糖控制時，可將劑量提升至每天 25 mg。2.7 腎功能不全者：不論腎功能如何，皆可使用 Empagliflozin 10 mg。由於經驗有限：針對透析病人：不建議使用 Jardiance 作為起始治療。若 eGFR 低於 30 mL/min/1.73m²，則 empagliflozin 建議劑量限於 10 mg，且如有需要，應考慮額外的降血糖治療。3 禁忌：對 empagliflozin 或 JARDIANCE 中其他賦形劑產生嚴重過敏反應，例如曾發生血管性水腫。4. 不良反應：酮酸中毒、體液容量減少、泌尿生殖系統感染，包括尿路敗血症、腎盂腎炎、會陰部壞死性筋膜炎（弗尼爾氏壞疽）及生殖器黴菌感、併用胰島素與胰島素促分泌物質降發生的低血糖、過敏反應、低密度脂蛋白膽固醇 (LDL-C) 上升。

修正日期：2025 年 12 月　核定日期：2026 年 05 月

Boehringer Ingelheim
台灣百靈佳殷格翰股份有限公司
台北市民生東路三段2號12樓
電話：(02)2503-2636

PC-TW-107226-10-Aug-2026

CONGRESS INFORMATION



Congress Overview

Congress Name	The 38th World Congress of Internal Medicine (WCIM 2026)
Congress Theme	AI, Medicine, and Humanity into the Future
Date	November 12 (Thu.) – November 15 (Sun.), 2026
Venue	Taipei Nangang Exhibition Center, Hall 2 (TaiNEX 2) No.2, Jingmao 2nd Rd., Nangang District, Taipei, Taiwan
Organized By	International Society of Internal Medicine (ISIM) Taiwan Society of Internal Medicine (TSIM)
Website	https://wcim2026.org/

Key Events

Event	Date	Time	Location
Opening Ceremony	Nov. 13, 2026 (Fri.)	17:30-18:30	701BC, 7F, TaiNEX 2
Welcome Reception	Nov. 13, 2026 (Fri.)	18:30-20:00	701D, 7F, TaiNEX 2
*Gala Dinner	Nov. 14, 2026 (Sat.)	18:30-21:00	The Grand Ballroom, 12F, Grand Hotel Taipei
Closing Ceremony	Nov. 15, 2026 (Sun.)	12:00-12:50	701BC, 7F, TaiNEX 2

*Pre-registration and payment are required for the Gala Dinner.

Certificate of Attendance/Presentation

All registered participants who check in on-site will receive a Certificate of Attendance via email after the Congress. Presenters will also receive a Certificate of Presentation.

Admission Badges

Admission badges will be provided upon registration at the Congress venue. Attendees are requested to wear their badges for identification purposes and to gain admission to various sessions and exhibitions.

Registration Type	Congress Kit	Opening/ Closing Ceremony	Scientific Sessions	Lunch Symposium / Satellite Symposium	Welcome Reception	Exhibition Area (Incl. Coffee Break)
VIP / SPEAKER / MODERATOR	✓	✓	✓	✓	✓	✓
DELEGATE	✓	✓	✓	✓	✓	✓
ACCOMPANYING PERSON		✓			✓	✓
EXHIBITOR		✓		Sponsored Sessions Only	✓	✓

Congress APP

Step 1: Search "**The Event App by EventsAir**" in your App Store/Google Play Store or scan the below QR code to download it to your mobile phone.

iOS (App Store)

Android (Google Play Store)

Step 2: Enter the Event Code "**WCIM2026**" and log in using either:
- Your registered account and password from the WCIM 2026 Registration Site.
- Your primary email with the pin code provided in the congress reminder.

701A Wi-Fi

Wi-Fi : WCIM2026
Password : wcim2026

Congress Services

Registration Desk

Date	Service Hours	Location
Nov. 12, 2026 (Thu.)	12:30-17:00	701A 7F, TaiNEX 2
Nov. 13, 2026 (Fri.)	08:30-17:00	
Nov. 14, 2026 (Sat.)	08:30-17:00	
Nov. 15, 2026 (Sun.)	08:30-14:00	

Speaker Ready Room

Date	Service Hours	Location
Nov. 12, 2026 (Thu.)	12:00-17:00	703 7F, TaiNEX 2
Nov. 13, 2026 (Fri.)	08:00-17:00	
Nov. 14, 2026 (Sat.)	08:00-16:30	
Nov. 15, 2026 (Sun.)	08:00-11:30	

Exhibition

Date	Service Hours	Location
Nov. 12, 2026 (Thu.)	13:00-17:00	Exhibition Area 7F, TaiNEX 2
Nov. 13, 2026 (Fri.)	09:00-17:00	
Nov. 14, 2026 (Sat.)	09:00-17:00	
Nov. 15, 2026 (Sun.)	09:00-12:00	

Coffee Break

Date	Service Hours	Location
Nov. 12, 2026 (Thu.)	14:40-15:10 15:30-16:00	Exhibition Area 7F, TaiNEX 2
Nov. 13, 2026 (Fri.)	10:40-11:10 15:20-15:50	
Nov. 14, 2026 (Sat.)	10:30-11:10 14:30-15:00	
Nov. 15, 2026 (Sun.)	10:40-11:10	

Luggage Room

Date	Service Hours	Location
Nov. 12, 2026 (Thu.)	12:30-16:30	701A 7F, TaiNEX 2
Nov. 13, 2026 (Fri.)	08:30-16:30	
Nov. 14, 2026 (Sat.)	08:30-16:30	
Nov. 15, 2026 (Sun.)	08:30-13:30	

Congress Lunch

Date	Service Hours	Location
Nov. 13, 2026 (Fri.)	12:00-13:30	7F, TaiNEX 2
Nov. 14, 2026 (Sat.)	12:00-13:30	

* Lunch boxes will be provided at each Lunch Symposium.

More Information

Scan the QR code to access the cloud folder containing congress-related information, including General Information, Shuttle Bus Information, and other relevant congress materials.

At Moderna, we are working to **deliver** the greatest possible impact to **people** through mRNA **medicines.**







moderna®

Visit Moderna's official website for more information

TW-MRNA-2600025, Jun 2026

Oral Presentation

Date: Nov. 14, 2026 (Sat.)

Location: 702, 7F, TaiNEX 2

** Presentations will be evaluated for the Oral Presentation Awards after all sessions conclude. Winners will be announced at the Gala Dinner.*

Slide Check & Revision Guidelines

- All slides should be pre-submitted. If you need to make minor updates, please preview and verify them in the Speaker Ready Room (703, 7F, TaiNEX 2) at least 2 hours before your scheduled session.
- **Content:** Presentation content must remain consistent with your accepted abstract. Only minor adjustments are permitted.
- **File Format:** PowerPoint (.pptx) or PDF, 16:9 Landscape (Keynote is NOT accepted).
- **Embedded Media:** Not supported.
- **Language & Quality:** All text and titles must be in English. Please ensure all figures are clear and high-resolution.

Presenting Schedule

Each Presenter is allotted 8 minutes for presentation and 2 minutes for Q&A.

Session 1: 09:00-11:00

Session 2: 11:20-13:20

Session 3: 13:40-15:40

E-poster Presentation

Viewing Hours: Nov. 12 (Thu.), 12:00 PM - Nov. 15 (Sun.), 12:00 PM, 2026

Location: 7F, TaiNex 2, North East Corner and South East Corner

Self-Service Viewing: Attendees are welcome to browse all accepted abstracts at their own pace using the touch-screen kiosks throughout the congress hours.

** No on-site author presentations are scheduled at the stations.*

** E-Poster Award winners will be announced at the Gala Dinner (The Grand Ballroom, 12F, The Grand Hotel Taipei).*

How to Find a Poster

Tap the screen to navigate the directory. Posters can be browsed or filtered by:

- Paper Number
- Theme
- Author Name

Online Abstracts

For more information, please scan the QR code to view or download the complete PDF version of the online abstract book.

TW26OZM00012 2026/04

novo nordisk®

OZEMPIC® 胰妥讚® semaglutide injection

RYBELSUS® 瑞倍適® semaglutide tablets

一週一次 wegovy® 週纖達® semaglutide injection



Sema for all





Semaglutide 高品質減重・護心肝胰腎

高品質減重效果

wegovy® 週纖達®

適用於成人 BMI ≥30 或 BMI ≥27 至 <30 kg/m² 且至少 1 項體重相關共病如血糖異常及青少年（12歲以上）肥胖且體重 >60 kg 之飲食運動輔助療法

全面護心肝胰腎

OZEMPIC® 胰妥讚® semaglutide injection

RYBELSUS® 瑞倍適® semaglutide tablets 3 mg 7 mg 14 mg

wegovy® 週纖達® semaglutide injection 0.25 mg 0.5 mg 1 mg 1.7 mg 2.4 mg

【Semaglutide禁忌症】本身或家族有髓質甲狀腺癌 (medullary thyroid carcinoma, MTC) 病史，或罹患第二型多發性內分泌腫瘤症候群 (multiple endocrine neoplasia syndrome type 2, MEN 2)。已知對於對藥物活性成分或任一賦形劑過敏。瑞倍適® 錠 Rybelsus® Tablets 3mg, 7mg, 14mg 處方資訊摘要【警語】瑞倍適® 未曾針對有胰臟炎病史的病人進行研究，有胰臟炎病史的病人，應考慮使用其他抗糖尿病療法。不可用於治療第一型糖尿病或糖尿病酮酸中毒。【不良反應】臨床試驗最常通報的不良反應是胃腸道問題，包括噁心（極常見）、腹瀉（極常見）及嘔吐（常見）。胰妥讚® 注射劑 Ozempic® solution for injection 處方資訊摘要【警語】Semaglutide 不應用於第一型糖尿病病人或治療糖尿病酮酸中毒。Semaglutide 也不能替代胰島素。【不良反應】臨床試驗最常通報的不良反應是胃腸道問題，包括噁心（極常見）、腹瀉（極常見）、嘔吐（常見）、週纖達® 諾特筆® Wegovy® solution for injection in pre-filled pen (FlexTouch®) 處方資訊摘要【警語】週纖達®不應與其他含semaglutide 的產品或任何其他GLP-1 受體促效劑併用。【不良反應】臨床試驗最常通報的不良反應爲胃腸道症狀，包括嘔吐 (極常見)、腹瀉 (極常見)、噁心 (極常見)、便祕 (極常見)、嗯心 (極常見)等。*詳細內容請參閱藥品仿單。

台灣諾和諾德藥品股份有限公司 | 台北市敦化南路二段 207 號 10 樓 | 網址：https://www.novonordisk.com.tw | 電話：02-77529030 | 傳真：02-23770111

北市衛藥廣字第115030187號 僅供醫療專業人員參考

寶比黴素® 注射劑

Bobimixyn®

Polymyxin B Sulfate for Injection 500,000U

STRIKE EARLY

DEFEAT MDR-GNB



Empiric Partners United for Life

Abbreviation: HCPs, healthcare professionals; MDR-GNB, multidrug-resistant gram-negative bacteremia

Add: 3F., No.3-1, Park St., Nangang Dist., Taipei City 11503, Taiwan R.O.C.
Tel: +886-2-26525999
Web: https://eng.tty.com.tw

TTY BIOPHARM 台灣東洋藥品

For HCPs Only.
See prescribing information before use.

Lin BioScience


LBS-007: A Novel Targeted Therapy for R/R Acute Leukemia

INTRODUCTION

LBS-007 is a **non-adenosine triphosphate (ATP)-mimetic inhibitor** of cell division cycle 7 (CDC7) kinase, a key regulatory protein of the cell cycle that initiates and maintains cell replication by phosphorylating MCM proteins of the DNA helicase complex.
Acute myeloid leukemia (AML) is a rapidly proliferating cancer characterized by high replication stress and DNA damage. Inhibition of CDC7 disrupts the ability of cancer cells to overcome replication stress and DNA damage. LBS-007 as a CDC7 inhibitor, represent a novel therapeutic opportunity to relapsed or resistant acute leukemias and currently in Phase 1/2 clinical evaluation.

MECHANISM OF ACTION

LBS-007 is an allosteric CDC7 kinase inhibitor that selectively kills cancer cells while sparing healthy ones. By binding to the CDC7-Dbf4 complex, it prevents MCM2 phosphorylation, halting DNA replication and G1-to-S cell cycle progression in normal cells. In rapidly proliferating cancer cells, this cell cycle inhibition causes checkpoint failure, resulting in the accumulation of DNA damage and ultimately leading to apoptotic cell death.



Reference: Jackson, P. Stopping replication, at the beginning. Nat Chem Biol 4, 331–332 (2008).

LBS-007-CT01 SUMMARY

Phase 1/2
(Phase 2 dose expansion after determining optimal dose in Phase 1)

Enrollment	Estimated to enroll 90 patients
Sites	Australia, Taiwan, US, China
Masking	Open Label
Treatment duration	7 consecutive days for one 28-day cycle
Primary measures	Safety, tolerability, optimal dose, and PK profile of LBS-007
Other measures	Efficacy of LBS-007
Key Inclusion Criteria	Aged ≥ 18, with confirmed relapsed or resistant AML or ALL, ineligible for standard therapies with an ECOG of 0 to 2.

MAJOR MILESTONES

- **2018/03**
  Received FDA ODD for treatment of ALL.
- **2023/02**
  Approved by the CALHN HREC to conduct Phase I/II clinical trials for AML and ALL in AU.
- **2023/08**
  Approved by TFDA to conduct Phase I/II clinical trials for AML and ALL in TW.
- **2024/07**
  Received FDA ODD for treatment of AML.
- **2024/10**
  Passed the US FDA IND review for human clinical trials (Acute leukemia).
- **2024/11**
  Fast Track Designation for treating AML from the U.S. FDA.
- **2025/09**
  Approved by the NMPA to conduct Phase I/II clinical trials for AML and ALL in CH.

SCIENTIFIC PROGRAMS



Program at a Glance

Thursday, November 12, 2026

	701BC		701D		701EF		702	
Afternoon Session	1300 | 1340	**Special Lecture** Modernizing Cardiorenal Care: Pragmatic Use of SGLT2 and RAAS Inhibitors	1300 | 1700	**AI Lecture** Smart Healthcare x Innovative Tech: Future Applications Showcase & Networking	1300 | 1440	**Symposium** Phenotype-Guided Therapeutic Pathways for Hypertension	1300 | 1600	**ISIM Board Meeting** (Non-Public Event)
	1350 | 1530	**Symposium** Precision Medicine in Kidney Disease: From Bench to Bedside			1440 | 1510	**Coffee Break**		
	1530 | 1600	**Coffee Break**			1510 | 1650	**Symposium** Comparative Internal Medicine Training and Practice Systems		
	1600 | 1640	**Special Lecture** Current Treatment of Hypercholesterolemia for Atherosclerotic Cardiovascular Disease						

Friday, November 13, 2026

		701BC	701D	701EF	702
Morning Session	0900 | 0950	**Special Address** Twin Pillars of Gastrointestinal Cancer Prevention: Messages from Taiwan to the World			
	1000 | 1040	**Keynote Speech** AI Transformation of Healthcare and Medical Education			
	1040 | 1110	**Coffee Break**			
	1110 | 1150	**Special Lecture** Global Strategies and Actions to Eliminate Hepatitis B Virus Infection	1110 | 1150 **Special Lecture** From Challenge to Benchmark: Two Decades of Pursuing Excellence in HBV and TB Risk Mitigation for Advanced Rheumatologic Therapies in Taiwan	1110 | 1150 **Special Lecture** Bridging Evidence and Social Implementation: New Horizons in Dementia Prevention Strategies	
1200 | 1330		**Lunch Symposium** Belite BIO	**Lunch Symposium** 台灣塩野義製藥	**Lunch Symposium** MSD	**Global Dignitaries Luncheon** (Invited Event)
Afternoon Session	1340 | 1520		**Symposium** One Health in Antimicrobial Resistance	1340 | 1520 **Symposium** New Horizon in Primary Care	1330 | 1700 **Global Forum** (Invited Event)
	1520 | 1550		**Coffee Break**		
	1550 | 1700			**Symposium** Medical Ethics and Gender Issues (Mandarin Chinese)	
	1730 | 1830	**Opening Ceremony**			
	1830 | 2000		**Welcome Reception**		

Saturday, November 14, 2026

	701BC		701D		701E		701F		702	
Morning Session	0900 | 1030	**Symposium** Application of Artificial Intelligence in the Management of Kidney Disease	0900 | 1040	**Symposium** The New Paradigm of Liver-Cardiovascular-Kidney-Metabolic (LCKM) Syndrome	0900 | 1040	**Symposium** Precision Medicine in Modern Oncology: From MRD Detection to Multidisciplinary Care	0900 | 1040	**Symposium** From Malnutrition to Metabolic Epidemic in One Generation: International Perspectives	0900 | 1100	**Short Oral Presentation**
	1030 | 1110	**Coffee Break**	1040 | 1050	**Coffee Break**	1040 | 1100	**Coffee Break**	1040 | 1110	**Coffee Break**		
	1110 | 1150	**Special Lecture** Human-Centered AI for Cancer Pathology: Advancing Diagnosis, Prognosis, and Precision Oncology	1050 | 1150	**Joint Symposium ACP/ISIM** Global Care Gap: Physician Shortages in Rural and Underserved Area	1100 | 1150	**Satellite Symposium** Boehringer Ingelheim	1110 | 1150	**Special Lecture** Artificial Intelligence in Hematology: From High-Dimensional Diagnostics to Precision Therapeutics	1120 | 1320	**Short Oral Presentation**
1200 | 1330	**Lunch Symposium** GSK		**Lunch Symposium** Boehringer Ingelheim		**Lunch Symposium** novo nordisk		**Lunch Symposium** moderna			
Afternoon Session	1340 | 1430	**Special Lecture** Harnessing AI and Multi-Omics Data to Advance Translational Cancer Research	1340 | 1430	**Satellite Symposium**			1340 | 1640	**ISIM General Assembly Meeting** (Non-Public Event)	1340 | 1540	**Short Oral Presentation**
	1430 | 1500	**Coffee Break**								
	1500 | 1640	**Symposium** Generative Artificial Intelligence in Digestive Medicine: Redefining Primary and Specialty Care	1500 | 1540	**Special Lecture** From Talent to National Policy: A Pioneering Framework for Lung Cancer Screening Among Never-Smokers in Taiwan	1500 | 1640	**Symposium** I.M. Successful: Futureproofing Your Career in Internal Medicine				
			1550 | 1640	**Satellite Symposium** Lilly						
	1830 | 2100	**Gala Dinner (Ticketed Event)**								

Sunday, November 15, 2026

	701BC		701D		702	
Morning Session	0900 | 1040	**Symposium** Holistic Care of Cardiovascular-Kidney-Liver-Metabolic Syndrome	0900 | 1040	**Symposium** Adult Vaccination and Respiratory Inflammation Forum	0900 | 1020	**Joint Symposium ISIM / EFLM** Laboratory and Internal Medicine Closely Together
			1040 | 1110	**Coffee Break**		
			1110 | 1150	**Special Lecture** Diabetes Mellitus and Heart Failure: Impact from Taiwan to Asia and the World		
	1200 | 1250	**Closing Ceremony**				
			1300 | 1400	**TSIM Annual Meeting** (Non-Public Event)		

韋立得®

不受腎功能[1]與食物[1]影響的B肝口服藥物*
單一劑量固定一天一顆[1]，融入各種生活型態
簡單治療，陪伴患者更長遠的未來

0%
Detectable resistance over 8 years[2]

97-98%
HBeAg negative Patients with HBV DNA < 29 IU/ml over 8 years[2]

86-89%
HBeAg negative Patients achieved ALT Normalizationover 8 years (central lab cutoff)[2]

提供不同生活形態的病患族群單一化治療
例如忙碌的上班族、共病的長青族、特殊B肝預防族群
具有卓越的療效[2]、安全性[2]
服藥方便[2]更大幅提升患者醫囑性以確保良好的疾病控制[3]



REFERENCE:
1. 衛福部食藥署核准之韋立得Vemlidy® 中文仿單
2. M Buti, et al. Aliment Pharmacol Ther. 2024;60:1573-1586
3. WJ Shin, et al. Am J Gastroenerol. 2018;113;998-1008
*不建議用於末期腎病且未接受長期血液透析的病人

韋立得® 膜衣錠
VEMLIDY® (tenofovir alafenamide)

適應症：適用於治療6歲以上且體重至少25公斤之慢性B型肝炎病人。**用法及用量：**在開始使用VEMLIDY之前，應檢測病人是否患有HIV-1感染症。不可單獨使用VEMLIDY治療HIV感染症病人。**成人和6歲以上且體重至少25公斤之兒童病人的建議劑量：**VEMLIDY用於成人和6歲以上且體重至少25公斤之兒童病人的建議劑量為每日一次口服一顆25毫克錠劑。**腎功能不全病人的劑量：**對於估計肌酸酐廓清率高於或等於15毫升/分鐘的病人，或末期腎病(ESRD，估計肌酸酐廓清率低於15毫升/分鐘)但接受長期血液透析的病人，並不須調整VEMLIDY的劑量。血液透析當日，待血液透析治療完成後再投與VEMLIDY。VEMLIDY不建議用於末期腎病且未接受長期血液透析的病人。對腎功能不全的兒童病人，目前尚無任何資料可以據以做出劑量建議。**肝功能不全病人的劑量：**對肝功能不全的病人，並不須調整VEMLIDY的劑量。**警語與注意事項：**依據96週的分析結果，發現≥5%的不良反應(所有等級)包括：頭痛、腹痛、咳嗽、背痛、疲倦、噁心、關節痛、腹瀉和消化不良。如有發生或疑似發生上述不良反應，請詳見仿單並做出臨床適當處理。臨床上可能發生的風險包括乳酸中毒/嚴重肝臟腫大合併脂肪肝、停止治療後B型肝炎惡化、合併感染HBV與HIV-1之病人發生HIV-1抗藥性的風險、新發生的腎功能受損或腎功能受損惡化，如有發生或疑似發生上述不良反應，請詳見仿單並做出臨床適當處理。如果用藥過量，應監視病人是否出現毒性反應的跡象。VEMLIDY使用過量時的處置方式為一般的支持性措施，包括監測生命徵象與觀察病人的臨床狀態。血液透析可有效移除tenofovir，萃取係數約為54%。

特殊族群之使用：對於懷孕的婦女，現有的APR資料顯示，tenofovir alafenamide（TAF)的整體出生缺陷風險和亞特蘭大大都會先天缺陷計劃(MACDP)中美國參考族群的重大出生缺陷背景發生率(2.7%)並無統計學上明顯差異。**對於哺乳期間的母親**，已發表之文獻的資料顯示，TAF和tenofovir會出現於人類的乳汁。已發表之文獻的資料並未顯示TAF會對餵哺母乳的幼童造成不良影響。目前並無任何關於TAF對乳汁生成作用之影響方面的資料。應一併考慮餵哺母乳對於發育與健康之效益、母親對VEMLIDY的臨床需求，以及VEMLIDY或母親的基礎疾病對餵哺母乳之嬰兒的任何可能不良影響。**小兒之使用**，在長達96週的試驗1092中，對6至未滿18歲且體重至少25公斤的兒童病人(N=59)使用VEMLIDY治療慢性HBV感染症的藥物動力學、安全性和有效性已經確立。和成人中的觀察結果相比較，在藥物動力學或安全性方面並未觀察到任何具臨床意義的差異。VEMLIDY用於未滿6歲或體重不足25公斤之慢性HBV感染症兒童病人的安全性及有效性尚未確立。**老年病人**，在臨床試驗中曾針對89位65歲(含)以上的受試者投予VEMLIDY。在老年受試者與18至小於65歲的受試者之間，並未發現任何具臨床意義的安全性或療效方面的差異。請存放於30°C(86°F)以下的環境。其他資訊請詳見衛福部最新核准之仿單

使用前請詳閱說明書警語及注意事項
衛部藥輸字第027086號
北市衛藥廣字第115090113號

Vemlidy® 韋立得®
tenofovir alafenamide 25mg tablets

TW-VEM-0225

GILEAD 吉利德科學台灣有限公司

Detailed Program

Thursday, November 12, 2026

Special Lecture – Modernizing Cardiorenal Care: Pragmatic Use of SGLT2 and RAAS Inhibitors

Time: 13:00 – 13:40
Room: 701BC
Moderator: Ming-Ju Wu
Speaker: William Herrington

Symposium – Phenotype-Guided Therapeutic Pathways for Hypertension

Time: 13:00 – 14:40
Room: 701EF
Moderator: Ming-Fong Chen

Time	Topic	Speaker
13:00 – 13:30	Morning Hypertension and Sympathetic Activation: From ABPM Phenotyping to Digital Therapeutics	Renata Cifkova
13:30 – 14:00	Metabolic Hypertension Across Populations: GLP-1 Receptor Agonists, SGLT2 Inhibitors, And Guideline Evolution	Vin-Cent Wu
14:00 – 14:30	From Polypills to Renal Denervation: Adherence and a Global Implementation Roadmap	Tzung-Dau Wang

Symposium – Precision Medicine in Kidney Disease: From Bench to Bedside

Time: 13:50 – 15:30
Room: 701BC
Moderators: Maaliddin Biruar, Jin-Shuen Chen

Time	Topic	Speaker
13:50 – 14:15	Precision Prevention for Kidney Health: Balancing Innovation with Implementation	Adrian Liew
14:15 – 14:40	Precision Diagnosis: Polygenic Risk Score (PRS) for Risk Stratification in CKD Patients	I-Wen Wu
14:40 – 15:05	Precision Nutrition: Gut-renal Axis in Kidney Patients	Szu-Chun Hung
15:05 – 15:30	Precision Therapy: Personalized Therapy for Immune-related Glomerulonephritis	Muh Geot Wong

Thursday, November 12, 2026

Symposium – Comparative Internal Medicine Training and Practice Systems

Time: 15:10 – 16:50
Room: 701EF
Moderators: Piotr Gajewski, Kuan-Yu Chen

Time	Topic	Speaker
15:10 – 15:30	Training and Daily Practice of the Internists in the USA	Tammy Lin
15:30 – 15:50	Training the Internists of the Future: Latin American Educational Leadership	Miguel Angel Falasco
15:50 – 16:10	Training and Daily Practice of the Internists in Taiwan	Wang-Huei Sheng
16:10 – 16:30	Needs Assessment for Career Development of the Internists in Taiwan	Chia-Ter Chao
16:30 – 16:50	The Future Role of Internists in the Evolution of Internal Medicine	Pascual Valdez

Special Lecture – Current Treatment of Hypercholesterolemia for Atherosclerotic Cardiovascular Disease

Time: 16:00 – 16:40
Room: 701BC
Moderator: Ming-Shien Wen
Speaker: Yi-Heng Li

Friday, November 13, 2026

Special Address –
Twin Pillars of Gastrointestinal Cancer Prevention: Messages from Taiwan to the World

Time: 09:00 – 09:50
Room: 701BC
Moderator: Shan-Chwen Chang

Time	Topic	Speaker
09:05 – 09:25	Primary Prevention of Gastric Cancer through Helicobacter pylori Screening and Eradication	Yi-Chia Lee
09:25 – 09:45	Two Decades of Population Colorectal Cancer Screening: Lessons Learned by Doing	Han-Mo Chiu

Keynote Speech –
AI Transformation of Healthcare and Medical Education

Time: 10:00 – 10:40
Room: 701BC
Moderator: Fa-Yauh Lee
Speaker: C. Jason Wang

Special Lecture –
Global Strategies and Actions to Eliminate Hepatitis B Virus Infection

Time: 11:10 – 11:50
Room: 701BC
Moderator: Pei-Ming Yang
Speaker: Jia-Horng Kao

Special Lecture –
From Challenge to Benchmark: Two Decades of Pursuing Excellence in HBV and TB Risk Mitigation for Advanced Rheumatologic Therapies in Taiwan

Time: 11:10 – 11:50
Room: 701D
Moderator: Eugene J. Kucharz
Speaker: Tsu-Yi Hsieh

Special Lecture –
Bridging Evidence and Social Implementation: New Horizons in Dementia Prevention Strategies

Time: 11:10 – 11:50
Room: 701EF
Moderator: Ding-Cheng Chan
Speaker: Hidenori Arai

Friday, November 13, 2026

Symposium – One Health in Antimicrobial Resistance

Time: 13:40 – 15:20
Room: 701D
Moderators: Feng-Yee Chang, Yee-Chun Chen

Time	Topic	Speaker
13:40 – 14:05	Companions in Antimicrobial Resistance: Examining Transmission of Common Antimicrobial-Resistant Organisms Between People and Their Dogs, Cats, and Horses	Diego Nobrega
14:05 – 14:30	Carbapenem-Resistant Gram-Negative Bacilli in Companion Animals in Southeast Asia	Pattrarat Chanchaithong
14:30 – 14:55	AMR Surveillance in Farms and Potential Solutions toward AMR Reduction	Yung-Chih Wang
14:55 – 15:20	AMR in the Aquatic Environments	Jiun-Ling Wang

Symposium – New Horizon in Primary Care

Time: 13:40 – 15:20
Room: 701EF
Moderators: Shao-Yi Cheng, Kuo-Chin Huang

Time	Topic	Speaker
13:40 – 14:05	The Next Horizon of Primary Care: Beyond Disease, Toward Living Well	Machiko Inoue
14:05 – 14:30	Beyond Longevity: Whole-Life Care as the New Horizon of Primary Care	Sun-Hyun Kim
14:30 – 14:55	Empowering Primary Care: The Evolution of Family Medicine in Taiwan and the Healthy Taiwan Deep Cultivation 888 Program	Wen-Yuan Lin
14:55 – 15:20	Primary Care in the Climate Crisis – Planetary Health as the New Horizon	Ming-Nan Lin

Symposium – Medical Ethics and Gender Issues (Mandarin Session)

Time: 15:50 – 17:00
Room: 701EF
Moderator: Huey-Ling Chen

Time	Topic	Speaker
15:50 – 16:40	Sexual Harassment in Healthcare: A Gender-Responsive 3P Approach	Lih-Rong Wang
16:40 – 17:00	Discussion	

Saturday, November 14, 2026

Symposium –
Application of Artificial Intelligence in the Management of Kidney Disease

Time: 09:00 – 10:30
Room: 701BC
Moderator: Yi-Wen Chiu

Time	Topic	Speaker
09:00 – 09:20	AI-ECG for Dyskalemia and Dyscalcemia	Shih-Hua Lin
09:20 – 09:40	Bridging the Gap from AKI Prediction to Recovery: The Role of AI and CDSS in Reshaping the AKI Trajectory	Tsai-Jung Wang
09:40 – 10:00	AI in Dialysis Care	Chia-Te Liao
10:00 – 10:20	Future Perspectives of Telemedicine	Masaomi Nangaku

Symposium –
The New Paradigm of Liver-Cardiovascular-Kidney-Metabolic (LCKM) Syndrome

Time: 09:00 – 10:40
Room: 701D
Moderators: Jia-Horng Kao, Richard Ceska

Time	Topic	Speaker
09:00 – 09:25	From MASLD to LCKM Syndrome: The Liver as a Central Driver of Multi-Organ Dysfunction	Liang Qiao
09:25 – 09:50	The Metabolic Dysfunction and Hormonal Crosstalk in LCKM Syndrome	Wei-Shiung Yang
09:50 – 10:15	The Liver-Kidney-Heart Axis. Chronic Kidney Disease as a Catalyst in LCKM Syndrome	Mai-Szu Wu
10:15 – 10:40	Cardiovascular Risks in Patients with Chronic Liver Disease: Shared Pathways and Clinical Consequences	Yen-Wen Wu

Symposium –
Precision Medicine in Modern Oncology: From MRD Detection to Multidisciplinary Care

Time: 09:00 – 10:40
Room: 701E
Moderators: Jen-Shi Chen, Chih-Hsin Yang

Time	Topic	Speaker
09:00 – 09:25	Minimal Residual Disease and Liquid Biopsy: Transforming Precision Cancer Care	Yao-Yu Hsieh
09:25 – 09:50	Antibody-Drug Conjugates: Redefining Targeted Cancer Therapy	Derek De-Rui Huang
09:50 – 10:15	Next-Generation Immunotherapy: Beyond PD-1/PD-L1	San-Chi Chen
10:15 – 10:40	The Pathology Slide as a Platform for Cancer Phenotyping	Kun-Hsing Yu

Saturday, November 14, 2026

Symposium – From Malnutrition to Metabolic Epidemic in One Generation: International Perspectives

Time: 09:00 – 10:40
Room: 701F
Moderators: Adri Kok, Feng-Hsuan Liu

Time	Topic	Speaker
09:00 – 09:25	Diabetes and Obesity in Latin America: Beyond Drugs—the Power of Community Interventions and Public Policy	Alejandro Cardenas
09:25 – 09:50	Cardiovascular Disease in the Metabolic Era: Primary Prevention in Resource-Limited Settings - Latin American Perspective	Yorlady Uchamocha Perez
09:50 – 10:15	Cardiovascular Disease in the Metabolic Era: Primary Prevention in Resource-Limited Settings — An Asian Perspective	Quazi Tarikul Islam
10:15 – 10:40	Metabolic Dysfunction-Associated Steatosis Liver Disease (MASLD/MASH): Challenges and Opportunities in Early Diagnosis and Management in Taiwan	Chih-Yuan Wang

Joint Session – Joint Symposium ACP/ISIM: Global Care Gap: Physician Shortages in Rural and Underserved Area

Time: 10:50 – 11:50
Room: 701D
Moderator: Virginia Hood

Time	Speaker
10:50 – 11:20	Sally Aman Nasution
11:20 – 11:50	Priya Radhakrishnan

Special Lecture – Human-Centered AI for Cancer Pathology: Advancing Diagnosis, Prognosis, and Precision Oncology

Time: 11:10 – 11:50
Room: 701BC
Moderator: Ching-Hsiung Lin
Speaker: Kun-Hsing Yu

Saturday, November 14, 2026

Special Lecture –
Artificial Intelligence in Hematology: From High-Dimensional Diagnostics to Precision Therapeutics

Time: 11:10 – 11:50
Room: 701F
Moderator: Hsin-An Hou
Speaker: Bor-Sheng Ko

Special Lecture –
Harnessing AI and Multi-Omics Data to Advance Translational Cancer Research

Time: 13:40 – 14:30
Room: 701BC
Moderator: Yuh-Min Chen
Speaker: Kang-Lin Hsieh

Symposium –
Generative Artificial Intelligence in Digestive Medicine: Redefining Primary and Specialty Care

Time: 15:00 – 16:40
Room: 701BC
Moderators: Ming-Lung Yu, Chun-Chao Chang

Time	Topic	Speaker
15:00 – 15:25	Generative AI in Medicine: Redefining Diagnosis and Care in Internal Medicine	Joseph Sung
15:25 – 15:50	Revolutionizing Upper GI Care: AI in Stomach Health	Yi-Chia Lee
15:50 – 16:15	Shaping the Future of Colorectal Health: AI in Colorectal Cancer Prevention and Disease Management	Han-Mo Chiu
16:15 – 16:40	The Human–AI Partnership: Ethics, Trust, and Multisystem Integration in Internal Medicine	Daniel Fu-Chang Tsai

Special Lecture –
From Talent to National Policy: A Pioneering Framework for Lung Cancer Screening Among Never-Smokers in Taiwan

Time: 15:00 – 15:40
Room: 701D
Moderator: Chong-Jen Yu
Speaker: Chao-Hua Chiu

Saturday, November 14, 2026

Symposium – I.M. Successful: Futureproofing Your Career in Internal Medicine

Time: 15:00 – 16:40
Room: 701E
Speakers: Robert Dobbin Chow, Mukta Panda, Tammy Lin
- Medical Student Education
- IM Residency Training
- Career Development for the Future IM Physician
- Sustainable Career Success
- Interactive Discussion Including Q/A

Short Oral Presentation 1

Time: 09:00 – 11:00
Room: 702

Time	Paper Number	Paper Title	Presenter
09:00 – 09:10	356	Mitochondrial Dysfunction in Lupus Neutrophils Link to Excessive Neutrophil Extracellular Traps, High Anti-dsDNA Antibody, and More Prominent Oxidative Stress	Yen Po Tsao
09:10 – 09:20	11	Effect of PM2.5 Exposure on the Risk of Incident Autoimmune Diseases	Yung-Feng Yen
09:20 – 09:30	84	Immunogenicity, Reactogenicity and Safety of mRNA-Based Seasonal Influenza and SARS-CoV-2 Multicomponent Vaccine, mRNA-1083, in Adults ≥50 Years in Taiwan	Yuchun Wang
09:30 – 09:40	362	Early Visceral Fat Reduction Precedes Weight Loss and Identifies Treatment Response in Obesity	Anna Lucatello
09:40 – 09:50	196	The Ceramide/S1P Rheostat in Glucose Homeostasis and Liver Injury: Dietary Normalisation Fails to Rescue S1P Lyase Knock-in Mice	Thang Nguyen Ngoc
09:50 – 10:00	443	Cardio-Kidney-Metabolic Syndrome in Motion: Disease-State Transitions and the Impact of GLP-1 Receptor Agonists, SGLT2 Inhibitors, and ARNI	Jing-Xing Li
10:00 – 10:10	360	Predicting Short-Term Clinically Significant Kidney Function Decline in CKD Stages 3–5: Development and External Validation of Machine Learning Models Using Routine Electronic Health Records	Trung Toan Duong
10:10 – 10:20	220	Impact of Ambient Heat Exposure on Renal Function Decline in Chronic Kidney Disease: A Longitudinal Cohort Study in Taiwan	Po-Yun Chiu
10:20 – 10:30	143	HRV Triangular Index Identifies Early Diastolic Dysfunction and Unfavorable Filling Hemodynamics in Patients With Frequent PVCs and Preserved EF	Tien En Chen

10:30 – 10:40	280	Resting Heart Rate Is a Powerful Modifiable Target of Physical Activity for Cancer Mortality Prevention	Chien Hua Chen
10:40 – 10:50	14	Interpretable Photoplethysmography-Based Machine-Learning Model for Noninvasive Assessment of Systolic Blood Pressure	Chin-Nan Lin
10:50 – 11:00	407	A Real-Time Computer-Aided Barrett's Esophagus Detection System	Hsin-Yu Hung

Short Oral Presentation 2

Time: 11:20 – 13:20
Room: 702

Time	Paper Number	Paper Title	Presenter
11:20 – 11:30	208	Efficacy and Safety of Once-Weekly Semaglutide for Weight Management in Adults With Overweight or Obesity With or Without Type 2 Diabetes: A Real-World Clinical Trial in Bangladesh	Quazi Tarikul Islam
11:30 – 11:40	108	Cortisol Thresholds and Insulin Resistance: A Systematic Review and a Proposal of a Hierarchical Model of Metabolic Response to Cortisol Reduction	Hadeel Odeh
11:40 – 11:50	221	GLP-1 Receptor Agonists and Fertility: A Systematic Review of Mechanisms, Clinical Outcomes, and Unintended Pregnancies	Arwa Kamel Elsayed Ahmed
11:50 – 12:00	77	Prevalence of Primary Aldosteronism in the General Population, Hypertension, and Resistant Hypertension: A Systematic Review and Meta-Analysis	Po-Cheng Wu
12:00 – 12:10	271	Temporal Changes in Clinical Profile, Treatment Patterns, and Outcomes in Primary Aldosteronism: A Biennial Trend Analysis From 2014 to 2023	Wei-Ting Wang
12:10 – 12:20	113	Comparative Efficacy of Mineralocorticoid Receptor Antagonists in Chronic Kidney Disease: An Updated Systematic Review, Meta-Analysis, and Meta-Regression	Chiang-Chi Huang
12:20 – 12:30	404	Recurrent Severe Hypokalemia With Persistent Renal Chloride Wasting: A Diagnostic Challenge of Bartter-Like Syndrome	Chung-Mo Chang
12:30 – 12:40	382	KCCQ-CSS Endpoint Across Various Patient Profiles in HFpEF-Related Obesity With Semaglutide: A Systematic Review and Meta-Analysis	Jesilva Khairunnisa
12:40 – 12:50	122	Age-Related Differences in Clinical Presentation and Outcomes of Recurrent Pericarditis: Data From the International RUDRA Registry	Dmitrii Evdokimov
12:50 – 13:00	124	Treatment Patterns in Recurrent Pericarditis: Gap Between Guidelines and Real-World Practice	Dmitrii Evdokimov

13:00 – 13:10	151	Association of Genetic Variants With Minimum Steady-State Concentrations of Apixaban, Rivaroxaban, and Clopidogrel in Patients With Atrial Fibrillation After Acute Coronary Syndrome on Dual Antithrombotic Therapy	Anna Dubinina
13:10 – 13:20	166	Martorell Hypertensive Ischemic Ulcers: A Disease That Often Goes Unnoticed? Clinical Characteristics of 4 Years' Follow-Up	Evelyn Brito Chavez

Short Oral Presentation 3

Time: 13:40 – 15:40
Room: 702

Time	Paper Number	Paper Title	Presenter
13:40 – 13:50	128	Correlation of Abnormal Liver Function With Dengue Severity	Md Elias Bhuiyan
13:50 – 14:00	137	Clinical Spectrum, Quality of Life, and Disease Outcomes of Chikungunya Virus Infection: A Prospective Cohort Study From Bangladesh	Najeeb Mahiyuddin
14:00 – 14:10	298	Therapeutic Role of Colony-Stimulating Factor in Non-Neutropenic Sepsis	Mohamad Aljarad
14:10 – 14:20	368	Beyond the Pons: Seronegative Miller Fisher Syndrome as a Brainstem Stroke Mimic	Ahmed Mujtaba
14:20 – 14:30	270	A Clot That Was Not	Pankaj Kumar Handa
14:30 – 14:40	186	Implementing a Multidisciplinary Code Thrombolysis Pathway to Reduce Variability in Acute Stroke Care	Junaid Abdul Javeed Khan
14:40 – 14:50	167	Retrospective Analysis of Liver Biopsies Reported as Malignant: Clinical, Laboratory, and Pathological Parameters	Feyza Mine Öz Okuducu
14:50 – 15:00	191	High Systemic Inflammatory Burden Across Tumor Locations in Colorectal Cancer	Indy Frincy Vebrina
15:00 – 15:10	288	Plasma RNA Liquid Biopsy for Precision Stratification of Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease Among Arab Populations	Ammal Metwally
15:10 – 15:20	321	VR Reminiscence Therapy of Smart Healthcare in Day-Care Centers: Differential Activation of Learning Domains in VR and Non-VR Interprofessional Training	Cheng-Yu Chen
15:20 – 15:30	169	Burnout and Its Association With Psychological Well-Being Among Medical Students in Bangladesh: A Cross-Sectional Study	Mohammad Shahabul Huda Chowdhury
15:30 – 15:40	219	Clinical Learning Experiences of Undergraduate Medical Students in Bangladesh: A Mixed-Methods Study	Faruk Ahammad

Sunday, November 15, 2026

Symposium –
Holistic Care of Cardiovascular-Kidney-Liver-Metabolic Syndrome

Time: 09:00 – 10:40
Room: 701BC
Moderator: Wei-Shiung Yang

Time	Topic	Speaker
09:00 – 09:30	Decoding Regional Adiposity: From Depot-Specific Biology to Novel Clinical Predictors of Metabolic Complications	Feng-Chih Kuo
09:30 – 10:00	The Liver–Heart–Metabolic Axis: GLP-1–Based Therapies for MASLD, MASH, and Cardiometabolic Disease	Diana Payawal
10:00 – 10:30	Applications of Generative AI in Diabetes Management	Yao-Hsien Tseng

Symposium –
Adult Vaccination and Respiratory Inflammation Forum

Time: 09:00 – 10:40
Room: 701D
Moderator: Wang-Huei Sheng

Time	Topic	Speaker
09:00 – 09:30	Unlocking the Value of Shingles Vaccination in Super Aged Society	Reena Ladak
09:30 – 10:00	The Next Chapter of Adult Vaccination: The Evolving Role of mRNA	Gamal Elfatarany
10:00 – 10:30	Facing the Challenge of Chronic Lower Respiratory Diseases: Impact on the Clinical Practice of Internists	Jung-Yien Chien

Joint Session –
Joint Symposium ISIM / EFLM: Laboratory and Internal Medicine Closely Together

Time: 09:00 – 10:20
Room: 702
Moderators: Tomas Zima, Tjin-Shing Jap

Time	Topic	Speaker
09:00 – 09:20	Trends and Value-Based of Laboratory Medicine	Tomas Zima
09:20 – 09:40	From Biological Variation to Reference Change Value: Interpreting Sequential Laboratory Results	Hamit Hakan ALP
09:40 – 10:00	Current Concepts and Recent Advances in Hypercalcemia	Tjin-Shing Jap
10:00 – 10:20	Implementation of New Biochemical Tests in Hospitals: Application Procedures and Key Considerations	Bing-Heng Yang

Sunday, November 15, 2026

Special Lecture –
Diabetes Mellitus and Heart Failure: Impact from Taiwan to Asia and the World

Time: 11:10 – 11:50
Room: 701D
Moderator: Sally Aman Nasution
Speaker: Chung-Lieh Hung



Visit us at

Booth No. E03, E06

Welcome to Taiwan Excellence!
Savor hand-drip coffee, explore AI med tech & join our stamp rally!

Scan the QR code to learn more

Ad by TITA

Organized by TITA TAITRA

Sponsored Symposium Agenda

Lunch Symposium

Belite Bio (Swiss) AG

Date: Friday, November 13, 2026
Time: 12:00 – 13:30
Room: 701BC

Belite Bio® and Focus on Stargardt Disease		
Time	Topic	Speaker
12:00 – 13:30	Belite Bio® and Focus on Stargardt Disease	Lynn Huang

Taiwan Shionogi & Co., Ltd

Date: Friday, November 13, 2026
Time: 12:00 – 13:30
Room: 701D
Moderator: Wang-Huei Sheng

Time	Topic	Speaker
12:00 – 12:05	Opening	Wang-Huei Sheng
12:05 – 12:35	The Role of Cefiderocol in Current MDR Era	Ya-Sung Yang
12:35 – 12:45	Discussion 1	Wang-Huei Sheng Ya-Sung Yang
12:45 – 13:15	AI-Powered Infection Management: Advancing Antimicrobial Stewardship and Infection Surveillance	Shian-Sen Shie
13:15 – 13:25	Discussion 2	Wang-Huei Sheng Shian-Sen Shie
13:25 – 13:30	Closing	Wang-Huei Sheng

Merck Sharp & Dohme (I.A.) LLC, TW Branch

Date: Friday, November 13, 2026
Time: 12:00 – 13:30
Room: 701EF
Moderators: Tsung-Hsien Lin, Feng-Yee Chang

Advances in Preventive Medicine: From Precision LDL-C Management to Taiwan Adult Pneumococcal Immunization		
Time	Topic	Speaker
12:00 – 12:05	Opening	Tsung-Hsien Lin
12:05 – 12:40	Rethinking LDL-C Management in ASCVD Prevention	Chien-Yi Hsu
12:40 – 12:50	Discussion	Tsung-Hsien Lin Chien-Yi Hsu
12:50 – 12:55	Opening	Feng-Yee Chang
12:55 – 13:25	The Taiwan Experience: Translating Pneumococcal Epidemiology into Adult PCV Recommendation	Ching-Tai Huang
13:25 – 13:30	Discussion & Closing	Feng-Yee Chang Ching-Tai Huang

Lunch Symposium

GlaxoSmithKline plc

Date: Saturday, November 14, 2026
Time: 12:00–13:30
Room: 701BC
Moderator: Wen-Juei Jeng, Jee-Fu Huang

Navigating Functional Cure in Modern CHB Care with Coexisting MASLD		
Time	Topic	Speaker
12:00 – 12:05	Welcome and Introduction	Jee-Fu Huang
12:05 – 12:30	Preparing for the Functional Cure Era: How Will HBV Therapies and Biomarkers Reshape CHB Care?	Yen-Chun Liu
12:30 – 12:45	Case-based Expert Dialogue and Audience Q&A	Yen-Chun Liu Wen-Juei Jeng Tung-Hung Su Jee-Fu Huang
12:45 – 13:10	When CHB Meets MASLD: Implications for Viral Clearance, Fibrosis, and Long-Term Outcomes	Tung-Hung Su
13:10 – 13:25	Case-based Expert Dialogue and Audience Q&A	Yen-Chun Liu Wen-Juei Jeng Tung-Hung Su Jee-Fu Huang
13:25 – 13:30	Key Take-home Messages and Closing	Jee-Fu Huang

Boehringer Ingelheim Taiwan

Date: Saturday, November 14, 2026
Time: 12:00–13:30
Room: 701D
Moderators: Shih-Te Tu, I-Chang Hsieh

From Early Intervention to Multiorgan Protection: Advancing Care Across the CKML Continuum		
Time	Topic	Speaker
12:00 – 12:05	Opening	Shih-Te Tu
12:05 – 12:40	Early Intervention Strategies in CKLM : Improving Long-term Outcome in Type 2 Diabetes	Edy Kornelius
12:40 – 13:15	When Heart Failure Meets Atrial Fibrillation: Integrated "Whole-Heart" Treatments & Anticipated Asian Consensus Update	Chung-Lieh Hung
13:15 – 13:25	Panel Discussion	Edy Kornelius Chung-Lieh Hung
13:25 – 13:30	Closing	I-Chang Hsieh

Novo Nordisk Pharma (Taiwan) Ltd.

Date: Saturday, November 14, 2026
Time: 12:00–13:30
Room: 701E
Moderator: Jia-Horng Kao

Time	Topic	Speaker
12:00 – 12:35	Pioneering New Benchmark for High-Quality Weight Loss Management	Donna Shu-Han Lin
12:35 – 13:10	Fat Loss and Liver Health in the New Era of MASH Treatment	Tai-Chung Tseng
13:10 – 13:30	Q & A	Jia-Horng Kao Donna Shu-Han Lin Tai-Chung Tseng

Moderna Taiwan

Date: Saturday, November 14, 2026
Time: 12:00–13:30
Room: 701F
Moderator: Li-Min Huang

mRNA in Motion: From Respiratory Protection to the Next Frontiers of Medicine		
Time	Topic	Speaker
12:00 – 12:05	Opening & Welcome Remarks	Li-Min Huang
12:05 – 12:40	Closing the Protection Gap: Advances in Adult Respiratory Vaccination	Ting-Yu Yen
12:40 – 13:15	Beyond Vaccines: The Next Frontiers of mRNA Medicine	Gamal Elfatarany
13:15 – 13:30	Panel Discussion & Q&A	Li-Min Huang Gamal Elfatarany

Satellite Symposium

Boehringer Ingelheim Taiwan

Date: Saturday, November 14, 2026
Time: 11:00 – 11:50
Room: 701E
Moderator: Wei-Shiung Yang

Discuss recent advances of obesity management with the latest congress updates		
Time	Topic	Speaker
11:00 – 11:05	Opening	Wei-Shiung Yang
11:05 – 11:40	Advancing Obesity Management: Gaps, Opportunities, and Pathways to Organ Health	Jun-Sing Wang
11:40 – 11:50	Panel Discussion & Closing	Wei-Shiung Yang Jun-Sing Wang

Lin BioScience, Inc.

Date: Saturday, November 14, 2026
Time: 13:40 – 14:30
Room: 701D
Moderator: Irene Wang

Bringing Hope to the Incurable: Unlocking New Therapeutic Horizons for Acute Myeloid Leukemia		
Time	Topic	Speaker
13:40 – 13:45	Opening	Irene Wang
13:45 – 14:20	Bringing Hope to the Incurable: Unlocking New Therapeutic Horizons for Acute Myeloid Leukemia	Mark Frattini
14:20 – 14:30	Q&A / Discussion	Irene Wang Mark Frattini

Eli Lilly and Company (Taiwan), Inc.

Date: Saturday, November 14, 2026
Time: 15:50 – 16:40
Room: 701D
Moderator: Shih-Tzer Tsai

Pathways to Early Glycemic Control in Type 2 Diabetes: Where Does Weight Fit?		
Time	Topic	Speaker
15:50 – 15:55	Opening Remarks	Shih-Tzer Tsai
15:55 – 16:15	Early Glycemic Control in T2D: Integrating Weight Management into the Treatment Paradigm	I-Weng Yen
16:15 – 16:35	Panel Discussion and QA	I-Weng Yen Kuo-Meng Liao
16:35 – 16:40	Closing Remarks	Shih-Tzer Tsai I-Weng Yen Kuo-Meng Liao

FLOOR PLAN

Floor Plan


7F
UDB
N15
AMBOSS
N14
N05
Pfizer
Broad
N13
ERAbioteq
Jellox
N12
N11
GenMont
N10
N04
Boehringer Ingelheim
701d
701c
701b
701D
701B + C
Plenary Hall
Secretariat Office
FMA Registration
WCIM 2026 Registration
701H
701G
701E+F
FMA 贈品區
701h
701g
701f
B63
衛福部
第一三共
B53
C17
思耐得
信東
B50
華悅堂
B49
B62
臺大醫院
B61
標準
力大
B45
B60
一舜
B59
衡奕
力大
B35
宏福
B34
國網中心
S07
無國界醫生
S06
B39
合記
B38
六鵬


WOH
N09
Eastech
Veeva
N08
N07
Leltek
N06
N03
Lilly
N02
novo nordisk
N01
Lin BioScience
E05
moderna
701a
Luggage Storage
Charging Area
702
Entrance Display Board
701A
Speaker Ready Room
VIP Lounge
701e
Quanta
S05
ACP
S04
ISIM
S03
WCIM 2028
S02
S11
Elsevier
S10
LISTEN
S09
LI JET
S08
PIEBM
TFDA
S01
E06
TAIWAN EXCELLENCE
E07
SHONGCI
E-poster
Belite Bio
E01
GSK
E02
TAIWAN EXCELLENCE
E03
TEEMA
E04
E-poster
6F
602
603

Exhibitor Directory

Booth Number	Company Name
E01	Belite Bio (Swiss) AG
E02	GlaxoSmithKline plc
E03	Taiwan External Trade Development Council
E04	Taiwan Electrical and Electronic Manufacturers' Association Smart Healthcare Technology Committee
E05	Moderna Taiwan
E06	Taiwan External Trade Development Council
E07	Taiwan Shionogi & Co.,Ltd
N01	Lin BioScience, Inc.
N02	Novo Nordisk Taiwan
N03	ELI LILLY AND COMPANY(TAIWAN), INC.
N04	Boehringer Ingelheim Taiwan
N05	Pfizer Taiwan
N06	LELTEK INC.
N07	Eastech Co., Ltd.
N08	Veeva Systems Singapore Pte Ltd
N09	Woh Medical Co., Ltd
N10	GenMont Biotech Inc.
N11	ERA BIOTEQ ENTERPRISE CO., LTD
N12	JelloX Biotech Inc.
N13	Broad Pharmaceutical Co., Ltd.
N14	AMBOSS
N15	UNIVERSAL DEVELOPMENT BUSINESS
S01	Research Center for Biotechnology and Medicine Policy
S02	Philippine College of Physicians
S03	International Society of Internal Medicine
S04	American College of Physicians
S05	Quanta Computer
S08	Polish Institute for Evidence Based Medicine
S09	Li-Jet Medical Co.,Ltd.
S10	Listen
S11	Elsevier Taiwan L.L.C.

Accreditation Application
(Domestic Delegate Only)

WCIM 2026 會員報到、繼續教育學分說明

一、會員報到方式

報到證件

請會員 **本人親自報到**，並攜帶下列任一證件：

- 身分證
- 其他 **貼有本人照片且有身分證字號** 之證明文件。

重要提醒： 學分報到須由會員本人辦理，不得由他人代為報到。

二、內科醫學會 A 類學分

（一）大會基本學分：A 類 10 點

於會議期間 **任一指定時段** 至 **701A Registration** 完成 **1 次報到**，即可取得 **內科醫學會 A 類 10 點**。

日期	可報到時間
11 月 12 日（四）	12:30–17:00
11 月 13 日（五）	08:30–17:00
11 月 14 日（六）	08:30–17:00
11 月 15 日（日）	08:30–14:00

只需於上述任一時段完成 1 次報到，不需每日重複報到。

（二）指定課程額外 A 類學分

除上述 10 點外，參加下列指定課程並於規定時間完成刷卡，可另外取得 A 類學分。

日期	課程	課程時間	報到地點及刷卡時間	額外學分
11 月 12 日（四）	Symposium: Comparative Internal Medicine Training and Practice Systems	15:10–16:50	701EF 講廳前 15:00–17:00	A 類 2 點
11 月 13 日（五）	Opening Ceremony	17:30–18:30	701BC 講廳內 16:40–17:00	A 類 1 點

三、內科醫學會 B 類學分

於下列指定時段至指定講廳完成刷卡，**每 1 指定時段可取得 B 類 3 點。**
同一時段如有多場課程同時進行，學分不重複計算。

日期	時間	類型	講廳	贊助廠商	學分
11月13日（五）	12:00-13:30	Lunch Symposium	701BC	Belite Bio	B 類 3 點
			701D	台灣塩野義製藥	B 類 3 點
			701EF	MSD	B 類 3 點
11月14日（六）	11:00-11:50	Satellite Symposium	701E	百靈佳殷格翰	B 類 3 點
11月14日（六）	12:00-13:30	Lunch Symposium	701BC	GSK	B 類 3 點
			701D	百靈佳殷格翰	B 類 3 點
			701E	諾和諾德	B 類 3 點
			701F	莫德納	B 類 3 點
11月14日（六）	13:40-14:30	Satellite Symposium	701D	仁新醫藥	B 類 3 點
11月14日（六）	15:50-16:40	Satellite Symposium	701D	禮來	B 類 3 點

四、其他專科醫學會學分

（一）完成大會報到即可取得之次專科學分

學會	認列學分
台灣心臟學會	B 類 15 分
台灣消化系醫學會	B 類 8 分
台灣胸腔暨重症加護醫學會	B 類 32 分
中華民國內分泌暨糖尿病學會	乙類 4 分
中華民國風濕病醫學會	A 類 2 分
中華民國免疫學會	10 分
中華民國癌症醫學會	腫瘤內科 A 類 3 分、腫瘤外科 A 類 3 分
台灣感染症醫學會	B 類 4 分
台灣腎臟醫學會	B 類 10 分
中華民國血液病學會	甲類 1.5 分
台灣老年學暨老年醫學會	乙類 17 分

（二）需另外報到始可取得之學分

1. 台灣家庭醫學醫學會

除大會報到外，須每日 **另外至 701 A 大會服務台 (Information) 持大會識別證刷卡報到**，始得取得學分。

日期	簽到時間	可取得學分
11 月 12 日（四）	12:30–17:00	乙類 4 點
11 月 13 日（五）	08:30–17:00	乙類 6 點
11 月 14 日（六）	08:30–17:00	乙類 6 點
11 月 15 日（日）	08:30–14:00	乙類 3 點

2. 台灣腎臟醫學會

須於指定時間 **至 701 BC 講廳前簽名**，始得取得學分。

日期	簽到時間	可取得學分
11 月 14 日（六）	09:00–10:40	A 類 5 分

五、C 類

衛生福利部認定

參加下列指定課程者，請於規定時間至指定講廳刷卡報到。

日期 課程時間	課程名稱	報到地點及 刷卡時間	學分類別
11 月 13 日（五） 13:40–15:20	One Health in Antimicrobial Resistance	701D 講廳前 13:30–15:30	感控 申請中
11 月 13 日（五） 15:50–16:40	Medical Ethics and Gender Issues (Mandarin Chinese)	701EF 講廳前 15:40–16:50	性別、倫理 申請中
11 月 15 日（日） 09:00–10:40	Adult Vaccination and Respiratory Inflammation Forum	701D 講廳前 08:50–10:50	感控 申請中

六、臺北市糖尿病共同照護學分

臺北市政府衛生局認列

日期 課程時間	課程名稱	報到地點及 刷卡時間	學分類別
11 月 14 日（六） 09:00–10:40	From Malnutrition to Metabolic Epidemic in One Generation	701F 講廳前 08:50–11:00	2 學分
11 月 15 日（日） 09:00–10:40	Holistic Care of Cardiovascular-Kidney-Liver-Metabolic Syndrome	701BC 講廳前 08:50–10:50	2 學分
11 月 15 日（日） 11:10–11:50	Diabetes Mellitus and Heart Failure: Impact from Taiwan to Asia and the World	701D 講廳前 11:00–12:00	1 學分

誌謝

本次第 38 屆世界內科醫學國際研討會承蒙下列單位之熱心協助，使得大會得以順利進行，謹此誌謝。

台灣呼吸治療學會
台灣高血壓學會
台灣消化系醫學會
台灣愛滋病學會
社團法人台灣急診醫學會
台灣癌症安寧緩和醫學會
社團法人中華民國糖尿病學會
臺灣兒科醫學會
Taiwanese Association of Diabetes Educators (TADE)
臺灣皮膚科醫學會
台灣精神醫學會
中華民國血液及骨髓移植學會
社團法人中華民國心臟學會
中華民國骨質疏鬆症學會
中華民國重症醫學會
台灣動脈硬化暨血管病醫學會
台灣微生物學會
台灣老年學暨老年醫學會
社團法人台灣肥胖醫學會
社團法人台灣專科護理師學會
臺灣醫學會
中華民國血液病學會
台灣婦產科醫學會
台灣感染症醫學會
中華民國內分泌學會
台灣外科醫學會
台灣安寧緩和醫學學會
社團法人台灣腦中風學會
台灣腎臟醫學會
中華民國免疫學會
中華民國風濕病學會
台灣胸腔暨重症加護醫學會

Taiwan ICT Smart Healthcare Pavilion (Booth A04)

Taiwan's Leading Industry Service Association



SHARE · COLLABORATE · PROSPER

Connecting Industry Strengths, Creating Global Competitive Advantage

Established in 1948, TEEMA provides diverse global services to its members, advances shared industry interests, and serves as a vital bridge between industry and government. With a mission to promote economic growth, TEEMA is one of Taiwan's eight major national business associations.

TEEMA has long been dedicated to advancing technological innovation and industrial development. In response to the rapid growth of smart healthcare and health technologies, TEEMA established the Smart Healthcare Technology Committee to connect industry, academia, and government, build a cross-sector platform for collaboration and exchange, and jointly promote innovation and industrial development in smart healthcare and health technologies.


3000+
Member Companies

17
Industry Sectors

922,470
Number of Employees

PRODUCTION VALUE in 2025


Taiwan's Total Manufacturing Production Value
US$721,214.27 Million



Taiwan's E&E Industries (from the Upper, Mid, to Down Stream Sectors) Production Value
US$507,603.17 Million

EXPORT in 2025

Taiwan's Total Export Value
US$640,738.719 Million



Taiwan's E&E Industries (from the Upper, Mid, to Down Stream Sectors) Export Value
US$502,233.82 Million

Sources: Department of Statistics, Ministry of Economic Affairs, The Department of Statistics, Ministry of Finance
Edited by TEEMA.

Smart Healthcare Technology Committee

TEEMA for Taiwan ICT Industry
Taiwan Electrical and Electronic Manufacturers' Association



Visit us at

Booth No. E03, E06

Aco Healthcare 奔騰智慧生醫 · AVer · CYP · eped · iProtin

MiiS · netown 真茂科技 · Wincomm a Portwell Company · wistron medtech · ZINEXTS

Welcome to Taiwan Excellence!
Savor hand-drip coffee, explore AI med tech & join our stamp rally!

Scan the QR code to learn more

Ad by TITA

Organized by TITA · TAITRA



38th WCIM 2026 Taipei Taiwan

Hosts:

WCIM 2026 Program Book